Q-omics provides the consensus-scored NDUFA13 profile across patient tissues and cancer cell-line models. NDUFA13 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NDUFA13 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, NDUFA13 protein abundance shows 22,596 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where NDUFA13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA13 survival associations across molecular data types. NDUFA13 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA13 RNA expression–survival associations across cancer types. High NDUFA13 expression shows unfavorable associations in ACC, UVM, UCS, SKCM and LIHC, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for NDUFA13 RNA expression.
This table summarizes NDUFA13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA13 shows higher tumor expression in LIHC, BRCA, COAD, BLCA, ESCA and UCEC. The LIHC box plot shows higher NDUFA13 RNA expression in tumor versus normal tissue (log2 FC = +0.943, t-test p < 0.001).
This table shows molecular features associated with NDUFA13 in patient tissues and cancer cell lines. In patient samples, NDUFA13 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
